Related Content
Search Google Scholar for:
More Information
Related Jobs from ScienceCareers
|
|
Science 11 February 2000: Vol. 287. no. 5455, p. 931 DOI: 10.1126/science.287.5455.931a
|
|
Technical Comments
NADH Shuttle and Insulin Secretion
In their report (1), Eto et al.
hypothesize that nicotinamide adenine dinucleotide (NADH) is the signal
for the coupling of glycolytic and mitochondrial glucose metabolism
that triggers insulin secretion. Their conclusions, based on their innovative and meticulous experiments, do not consider the possibility that the glycolytic end-product in the cytosol is not pyruvate, but
lactate. Thus, when lactate enters the mitochondrial tricarboxylic acid
cycle, it must first be converted to pyruvate by the lactate dehydrogenase (LDH) reaction that also produces NADH. The LDH reaction
is an important source of NADH that allows cellular utilization of
lactate as the sole oxidative energy substrate (2). Whether
or not the LDH-produced NADH plays a role in triggering insulin
secretion could be determined by use of the well-designed system
described in the report (1). Incubation of
mGPDH / islets with 22.2 mM glucose + aminooxyacetate (AOA) + (20 to 40 mM) lactate should provide ample
amounts of LDH-produced NADH. Alternatively, incubation of wild-type
(WT) islets with 22.2 mM glucose + iodoacetic acid (IAA) + AOA + (20 to 40 mM) lactate should work as well. Instead of IAA,
the use of a pharmacological dose of the glucose analog
2-deoxy-D-glucose might work. Performing these experiments,
one should be able to determine if the LDH reaction produces an NADH
signal and, if so, whether or not such a signal is sufficient to
trigger insulin secretion.
Avital Schurr
University of Louisville School of Medicine Louisville, KY 40292, USA E-mail: a0schu01{at}ulkyvm.louisville.edu
Ralphiel S. Payne
University of Louisville School of Medicine Louisville, KY 40292, USA E-mail: rspayn01{at}ulkyvm.louisville.edu
REFERENCES
-
K. Eto,
et al.,
Science
283, 981
(1999)
[Abstract/Free Full Text]
.
-
A. Schurr,
et al.,
Science
240,
1326
(1988)
[Abstract/Free Full Text]
;
J. D. Stittsworth Jr. and
T. H. Lanthorn,
Brain Res.
630,
21
(1993)
[CrossRef] [ISI] [Medline]
;
Y. Izumi,
et al.,
NeuroReport
5,
617
(1994)
[ISI] [Medline]
.
2 March 1999; accepted 23 June 1999
It has been known since the early 1980s
that the glycerol phosphate shuttle and the malate- aspartate shuttle
are important for glucose-induced insulin secretion
(1). These shuttles enable mitochondrial metabolism to
reoxidize NADH formed in the reaction catalyzed by the cytosolic enzyme
glyceraldehyde phosphate dehydrogenase (GAPDH). Eto et al.
(2) are to be congratulated for obtaining a mouse
deficient in mitochondrial glycerol phosphate dehydrogenase (mGPD), the
key enzyme of the glycerol phosphate shuttle, because there are no
known potent specific inhibitors of mGPD, which would be useful for
studying its role in insulin secretion. The major conclusion of Eto
et al. (2) is the observation that insulin
release and glucose metabolism were normal in pancreatic islets from
mice lacking mGPD and thus the glycerol phosphate shuttle, but when
AOA, an inhibitor of transaminases, was applied to these islets to
inhibit the malate-aspartate shuttle, insulin secretion was inhibited
(2). In their wild-type (WT) islets AOA inhibited aspartate
aminotransferase, but only minimally inhibited insulin release
(2). However, Eto et al. (2) did not
mention that others have seen inhibition of glucose-induced insulin
release in WT rat islets and mouse islets treated with AOA
(3). In regard to the site of action of IAA, the authors
cannot unambiguously conclude that inhibition of
[U-14C]glucose metabolism by IAA in WT islets is caused
in inhibition of only GAPDH (an idea crucial to their argument),
because numerous enzymes are attacked by IAA (4).
Eto et al. (2) also observed that in islets from
the mGPD-deficient AOA-treated mouse 14CO2
metabolism from [6-14C]glucose was inhibited, but
metabolism of [U-14C]glucose to
14CO2 was not inhibited. This is biochemically
impossible [see (5)].
Eto et al. conclude (2, p. 983), "We thus
hypothesized that abolition of insulin secretion observed in
mGPDH / islets treated with AOA was caused
not by an insufficient supply of pyruvate to mitochondria but by a halt
of NADH supply to mitochondria." This conclusion is untenable
because, without reoxidation of cytosolic NADH, glycolysis would be
inhibited at the triose phosphates, and formation of all subsequent
glycolytic intermediates, including pyruvate, would be decreased. A
minimal conclusion one could make from the data in the report might be
that there are only two NADH shuttles in the insulin cell, and
that either shuttle alone can support glucose-induced insulin
secretion. However, if both shuttles are inhibited, NADH reoxidation
would be decreased, which would inhibit glycolysis and pyruvate
formation and insulin release. Inhibition of cytosolic NADH
reoxidation, glycolysis, and pyruvate formation and metabolism are
essentially inseparable from one another (5).
Finally, some new information suggests that the conventional
thinking about the glycerol phosphate shuttle as only using NADH may be
oversimplified. At the normal pH of 7.1, the islet cytosolic glycerol
phosphate dehydrogenase (cGPD) prefers NADPH as a cofactor over NADH,
and there is evidence that enzyme-enzyme interaction influences the
preference of cGPD for NADPH over NADH (6). Furthermore, islets possess at least one shuttle capable of exporting NADPH equivalents from the mitochondria (7). Thus, in the
cell, a major role of cGPD might be to supply cytosolic NADP.
Michael J. MacDonald
Children's Diabetes Center University of Wisconsin Madison, WI 53706, USA E-mail: mjmacdon{at}facstaff.wisc.edu
Leonard A. Fahien
Department of Pharmacology University of Wisconsin Madison, WI 53706, USA
REFERENCES
-
M. J. MacDonald,
J. Biol. Chem.
256,
8287
(1981)
[Abstract/Free Full Text]
; Arch. Biochem. Biophys.
213, 643 (1982); Diabetes 39, 1461 (1990).
-
K. Eto,
et al.,
Science
283, 981
(1999)
.
-
M. J. MacDonald,
Arch. Biochem. Biophys.
213,
643
(1982)
[CrossRef] [ISI] [Medline]
;
___,
L. A. Fahien,
R.
J. Mertz,
R. S. Rana,
Arch. Biochem. Biophys.
299,
400
(1989)
;
W. J. Malaisse,
et al.,
Endocrinology
111,
392
(1982)
[Abstract]
.
-
H. Zollner, Handbook of Enzyme Inhibitors
(VCH, New York, 1989).
-
M. J. MacDonald,
Arch. Biochem. Biophys.
300,
201
(1993)
[CrossRef] [ISI] [Medline]
; Arch. Biochem. Biophys.
305, 205 (1993).
-
P. Probhakar,
et al.,
Arch. Biochem. Biophys.
360,
195
(1998)
[CrossRef] [ISI] [Medline]
;
L. A. Fahien,
et al.,
364,
185
(1999)
.
-
M. J. MacDonald,
J. Biol. Chem.
270,
20051
(1995)
[Abstract/Free Full Text]
.
18 March 1999; accepted 7 September 1999
Response: Schurr and Payne note that
lactate can be an alternative substrate that provides the cytosol with
NADH and pyruvate through a reaction catalyzed by LDH. However, lactate
at 40 mM could not restore the 22.2 mM glucose-induced insulin
secretion in mGPDH / islets treated
with 5 mM AOA, where activities of both the NADH shuttles were
blocked. Two possibilities might explain this result. One is that
LDH activity in the islets was too low to generate ample NADH and
pyruvate from lactate in the cytosol. Indeed, LDH activity reportedly
must be quite low to ensure aerobic glucose metabolism in cells
(1). The other is that although LDH activity was
sufficiently high to utilize lactate, the products, NADH and
pyruvate--which in combination may stimulate insulin secretion--were unable to do so because these conditions block the NADH shuttle system.
Glucose-induced insulin secretion is known to be abolished in the
presence of IAA, which inhibits glycolysis at a step catalyzed by
glyceraldehyde-3 phosphate dehydrogenase, before generation of
glucose-derived NADH (2). In wild-type islets treated with 1 mM IAA, lactate at 40 mM was also unable to restore the secretion. In
this case, the inability to restore secretion can again be explained by
low LDH activity in cells, but not by the blocking of the NADH
shuttle system when LDH activity is sufficiently high. If the ample
supply of NADH and pyruvate is not sufficient to cause insulin
secretion, then a third, hitherto unknown glycolysis-derived signal,
possibly originating from between 1,3-bisphosphoglycerate and
phosphoenolpyruvate, may be required for reconstitution of glucose-induced insulin secretion, a possibility that might be investigated by overexpressing LDH in cells.
Turning to the comments of MacDonald and Fahien, we note that our
report (3) demonstrated that the NADH shuttle system is
essential for glucose-induced insulin secretion by coupling glycolysis
with activation of mitochondrial metabolism, thereby promoting
efficient adenosine triphosphate generation in mitochondria. MacDonald
(4, 5) suggested the potential role of the glycerol
phosphate shuttle or the malate-aspartate shuttle in glucose-induced
insulin secretion, noting that mGPDH is expressed in islets 40 to
70 times as much as in liver, heart, or skeletal muscle and that
AOA, an inhibitor of the malate-aspartate shuttle, partially inhibits
glucose-induced insulin secretion. The absence of an inhibitor of the
glycerol phosphate shuttle, however, has made it difficult to
determine the role of the NADH shuttle system, composed of the
two distinct shuttles. We have directly demonstrated the role of
the system in glucose-induced insulin secretion by treating
mGPDH / islets with AOA.
AOA at 5 mM suppressed glucose-induced insulin secretion from
wild-type mice islets by ~15% in static incubation for 60 min (3). In perifusion, the small decrease was mainly explained
by impairment in the early part of the second-phase secretion. When we
applied 5 mM AOA to mGPDH / mice islets,
glucose-induced insulin secretion was almost completely abolished. The inhibition by AOA was dose-dependent, and the
half-maximal inhibitory concentration was ~1 mM at 22.2 mM glucose
(6). The apparent difference in the ~15%
inhibitory effect of 5 mM AOA on insulin secretion in wild-type islets
observed by us (3) and the ~60% inhibition observed by
other workers (5, 7, 8) may have its roots in the relative activity of the glycerol phosphate shuttle compared with that of the
AOA-sensitive malate-aspartate shuttle. The activity of the glycerol
phosphate shuttle may have been decreased during their incubation of
rat islets (detailed procedures of islet culture after isolation were
not described). We used the mouse islets within a few hours after
isolation for insulin secretion experiments. It is notable that 15-mM
glucose-stimulated insulin secretion is inhibited by more than 85% in
clonal INS-1 cells treated with as low as 0.25 mM AOA
(9).
Oxidation of [6-14C]glucose is thought to reflect
the TCA (trichloroacetic acid) cycle activity more precisely than that
of [U-14C]glucose, mainly because the isotope-labeled
carbons of [3-14C]glucose and
[4-14C]glucose are lost at a step catalyzed by pyruvate
dehydrogenase before entering the TCA cycle, although some portion of
them enters the cycle as [1-14C]oxaloacetate for
oxidation (10). This is not the case with glucose labeled in
position 1, 2, 5, or 6. In addition, oxidation of
[1-14C]glucose produces 14CO2
during the oxidative part of the pentose phosphate pathway.
In contrast to the prevailing hypothesis, our report clearly
demonstrates that glycolysis can proceed when the NADH shuttle system is halted, a proposition that might be explored through measurement of NAD+/NADH ratio in the cytosol. If the
ratio is comparable to wild-type islets, reoxidation of NADH to
NAD+ may be compensated for by other dehydrogenases present
in the cytosol, one candidate being the reaction catalyzed by LDH.
However, if that reaction predominates, [U-14C]glucose
oxidation in mitochondria should be decreased, which we did not observe
(3). Thus, dehydrogenases other than LDH are more
probable candidates. If the ratio is low, it may follow that
glyceraldehyde-3 phosphate dehydrogenase functions well enough to
maintain the normal glycolytic flux under the reduced cytosolic
conditions.
Kazuhiro Eto
Yoshiharu Tsubamoto
Takashi Kadowaki
Department of Metabolic Diseases Graduate School of
Medicine University of Tokyo 7-3-1 Hongo, Bunkyo-ku Tokyo,
113-8655, Japan E-mail: kadowaki-3im{at}h.u-tokyo.ac.jp
REFERENCES
-
N. Sekine,
et al.,
J. Biol. Chem.
269,
4895
(1994)
[Abstract/Free Full Text]
.
-
R. J. Mertz,
et al.,
J. Biol. Chem.
271,
4838
(1996)
[Abstract/Free Full Text]
.
-
K. Eto,
et al.,
Science
283, 981
(1999)
.
-
M. J. MacDonald,
J. Biol. Chem.
256,
8287
(1981)
.
-
___,
Arch. Biochem. Biophys.
213,
643
(1982)
.
-
K. Eto,
et al.,
J. Biol. Chem.
274,
25386
(1999)
[Abstract/Free Full Text]
.
-
M. J. MacDonald,
et al.,
Arch. Biochem. Biophys.
269,
400
(1989)
[CrossRef] [ISI] [Medline]
.
-
W. J. Malaisse,
et al.,
Endocrinology
111,
392
(1982)
.
-
H. Ishihara,
et al.,
J. Clin. Invest.
104,
1621
(1999)
[ISI] [Medline]
.
-
F. Schuit,
et al.,
J. Biol. Chem.
272,
18572
(1997)
[Abstract/Free Full Text]
.
6 May 1999; accepted 5 January 2000
|
|